Skip to content

Can A Prescribed Walking Program With or Without Monitoring Impact Dizziness in the Older Adults?

Can A Prescribed Walking Program With or Without Monitoring Impact Dizziness in the Older Adults?

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03403400
Enrollment
17
Registered
2018-01-18
Start date
2018-07-18
Completion date
2019-09-05
Last updated
2020-07-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dizziness

Brief summary

Dizziness is a common complaint reported by 30% of people above 65 years of age and by more than 50% of those 90 years of age and older.(1) Age-related decline in vestibular, musculoskeletal, and neurologic performances compounded by a vestibular pathology can result to debilitating physical and psychological consequences. Dizziness is associated with falls,(2) disability (3) and physical inactivity.(4) Walking for endurance is cited as one of the components of vestibular rehabilitation (VR) in the Clinical Practice Guideline for Peripheral Vestibular Hypofunction.(5) Although walking can offset the avoidance of physical activity from symptom provocation, no direct evidence has been found to support the effect of walking on postural and dynamic stability, function, and participation in people with dizziness. The primary purpose of this study is to evaluate the impact of walking as an exercise component of VR on both primary and secondary vestibular-specific outcome measures. The primary outcomes are mCTSIB, TUG test, DGI, and DHI, while the secondary outcomes are the total number of visits and length of interventions (in weeks). The second purpose is to evaluate whether pedometers increase the adherence of older adults with vestibular issues to a walking program. This will be measured by change in physical activity, as represented by International Physical Activity Questionnaire (IPAQ) Walking Metabolic Equivalent of Task (MET)-minutes/week and IPAQ Total Physical Activity MET-minutes/week scores from the IPAQ short form during the episode of care (admission and discharge) and on four-weeks follow-up compared to those patients who only received instructions to walk without a pedometer. The third purpose of this study is to establish test-retest reliability of the TUG test on older adults with dizziness. Lastly, the fourth purpose of this study to investigate if the TUG, DGI, and mCTSIB are significant and strong predictors of the DHI in older adults with dizziness. Protocol #1365169 Predictors of Disability in the Older Adults is being performed to supplement the number of subjects for the fourth objective of this study.

Detailed description

Research Design 1. Experimental Design. To answer the first and second study objectives, a pragmatic, randomized, prospective, clinical study on 54 older adults with dizziness will be utilized. This will be conducted at Florida Hospital Sports Medicine and Rehabilitation locations that offer vestibular therapy. These are in East Orlando and Winter Park. 2. Correlation Design. A correlation analysis will be performed on the data collected on 54 subjects in the experimental design to establish the test-retest reliability of the Timed Up and Go. 3. Cross-sectional Descriptive Design. A regression analysis will be performed on three predictors of the Dizziness Handicap Inventory, obtained from the data collected on 54 subjects in the experimental design and from Florida Hospital Sports Medicine and Rehabilitation Physical Therapy medical charts from June 2015 to June 2018 that met the inclusion and exclusion criteria that were outlined in the Protocol #1365169. For the experimental design that will be conducted at Florida Hospital locations, the following data will be collected as standard of care by the physical therapist during initial evaluation, and if more time is needed, during the first follow-up physical therapy appointment: mCTSIB, TUG, DGI, DHI, age, gender, body mass index, home situation, Functional Comorbidity Index (FCI) total, ability to drive, medications and insurance type. After the subject signs the informed consent prior to the tenth visit, the study coordinator will be notified by the research staff to conduct a retrospective chart review of the patient's medical record. The study coordinator will extract the following baseline measurements from the subject's medical record: DGI, mCTSIB, DHI, TUG and socio-demographic data that include age, gender, body mass index, home situation (lives alone or with social support), Functional Comorbidity Index (FCI) total, ability to drive (able or unable), medications for vertigo and insurance type (Medicare/Non-medicare). Based on the retrospective chart review, the study coordinator will determine if the subject is eligible to participate in the study. Visit 1: Once the study coordinator determined that the subject is eligible to participate in the study, the subject will be assigned a research number and will be randomized into one of the three intervention groups. The research staff can initiate or continue the VR program and initiate the research intervention according to the intervention group. For the test-retest reliability of the TUG test, there will be one practice trial followed by two final performances that will be included in the data analysis. The subject will also be asked to complete the IPAQ-short form questionnaire. The test-retest reliability of TUG and the IPAQ-short form questionnaire are for research purposes only. Visit 2: The research staff can initiate the research intervention according to the intervention group. Visit 3 to visit prior to discharge: The research staff can continue the VR and intervention according to the intervention group. Discharge or last visit: All outcome measures (DGI, TUG, mCTSIB, DHI and IPAQ) will be reassessed. Discharge scores for DGI, TUG, mCTSIB and DHI are standard of care, while IPAQ is for research purposes only. The total number of visits and length of interventions (in weeks) for every participant will be recorded as secondary outcome measures. These research data will be forwarded to the study coordinator, and will be stored in a locked cabinet and password protected Florida Hospital computer. Four-weeks after discharge: The study coordinator will conduct a follow up phone call to all subjects four weeks after discharge summary is completed to obtain the level of physical activity using the IPAQ short form questionnaire. This is for research purposes only. A follow-up on a subject will be discontinued if a subject is not reached after three attempts of follow-up phone call made on three different days between 30 and 45 days. Data analysis will commence once all the data from 54 subjects are collected. Sample Size Determination A priori power analysis predicting a large effect size (F=.25) determined that a total of 54 subjects (18 in each group), who met the inclusion and exclusion criteria will be needed, with alpha at the conventional value of .05 to achieve a .80 power, that includes an assumption of a dropout rate of 50% . Statistical Analysis Plan The results will be presented through the following tables with supporting explanations: * Clinical and sociodemographic characteristics of participants by group at baseline. * Comparisons of TUG, DGI, mCTSIB and DHI between the three intervention groups on admission and discharge. * Comparisons of self-reported walking activity (walking MET-min/week) and total self-reported energy expenditure (total physical activity MET-min/week) as determined from the IPAQ short form on admission, discharge and four-week follow-up between the three intervention groups * Comparisons of averages of compliance to step log recording and compliance rate for meeting step goal between the VRWP and VRW groups. Compliance is defined as low (\<33%), moderate (33%-75%) and high (\>75%) based on the step log or walking log. This grading of compliance was used by Hall and colleagues in their research on efficacy of gaze stability exercises in older adults with dizziness.(6) * Comparisons of total number of visits and length of interventions in weeks between the three intervention group. * Intraclass Correlation Coefficients for the Timed Up and Go test-retest reliability * Result of stepwise linear regression analysis for TUG, DGI, mCTSIB and DHI All interval and ratio data will be tested for normality prior to undertaking the data analysis. Descriptive statistics will be used to describe the characteristics of the sample and compare the three groups at baseline. This will include Analysis of Variance (ANOVA) for parametric and Chi Square for nonparametric sociodemographic and clinical data. Analyses will employ five repeated measures Analysis of Covariance (ANCOVA), adjusting for age, with two independent variables (group and time) and five outcome measures (TUG, DGI, DHI, mCTSIB and IPAQ short form). The adjustment of age is based on age-related decline. Intraclass Correlation Coefficient will be calculated to establish the test-retest reliability of the TUG and a stepwise linear regression with age as covariant will be conducted for all 54 subjects at baseline to determine if TUG, mCTSIB and DGI are predictors of DHI. Two-tailed test will be utilized to compare the compliance with step log recording and meeting step goals between the two walking groups (VRWP and VRW), and ANOVA to compare of total number of visits and total length of intervention in weeks between the three groups. Alpha for all analyses will be set at 0.05 to test for significant difference.

Interventions

BEHAVIORALVRWP Group

The VRWP group will have VR with an instruction to increase their number of steps daily to at least 3,000 steps using the pedometer (VR plus walking plus pedometer group). They will receive pedometers (Fitbit Zip), instructions on how to use the pedometer, step log forms, with home instruction handout to walk more at least more than ten minutes at a time. The participants will record on their activity log the number of steps shown on the step display at the end of the day. The daily step log form will be given to the research staff every visit for recording. The research staff will encourage their participants to increase their daily steps at least 10% until they achieve at least 3,000 steps daily.

BEHAVIORALVRW Group

The VR (control) group will follow the conventional VR physical therapy without the encouragement of walking and without specification of walking in the home exercise program.

Sponsors

Adventist University
CollaboratorOTHER
AdventHealth
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Experimental Design. To answer the study objective, a pragmatic, randomized, prospective, clinical study on 54 older adults with dizziness will be utilized. This will be conducted at Florida Hospital Sports Medicine and Rehabilitation locations that offer vestibular therapy. These are in East Orlando and Winter Park.

Eligibility

Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Age 65 years or older referred for physical therapy evaluation for symptoms of dizziness, postural instability, or both 2. Able to walk without the physical help of another person, with or with no assistive device 3. Able to follow commands and execute the examination and intervention instructions in the English language 4. Willing to participate in a phone interview four weeks after discharge 5. Able to provide informed consent

Exclusion criteria

1. Unstable medical issues, such as unstable or uncontrolled cardiovascular conditions, elevated blood pressure (Systolic greater than or equal to 140mmHg and diastolic greater than or equal to 90mmHg), orthostatic hypotension (a fall in systolic blood pressure of at least 20mmHg or diastolic blood pressure of at least 10mmHg when a person stands from a sitting or lying down position), uncontrolled metabolic disease, as determined by the evaluating physical therapist, documented in the Functional Comorbidity Index, vital signs and assessment portion of the initial evaluation. 2. History of falls from syncopal origin 3. Dizziness of central origin, such as stroke, head injuries, MS or PD; 4. Active BPPV (patients with positive dix hallpike and/or roll test) 5. Inability to walk without physical assistance.

Design outcomes

Primary

MeasureTime frameDescription
Modified Clinical Test of Sensory Integration for Balance (mCTSIB)Change from up to week 9 of treatment to up to 16 weeks of treatmentThe mCTSIB quantifies the ability of the patient to use information from somatosensory, visual and vestibular system effectively for postural stability. This test eliminated conditions 3 and 6 of the original CTSIB, which use an altered visual input (visual conflict dome). It is performed with the feet together, a modification from the original test, which is with feet apart.(7) The four conditions of mCTSIB are standing on firm surface eyes open, standing on firm surface eyes closed, standing on compliant surface eyes open, and standing on compliant surface eyes closed. The patient is timed for 30 seconds and the average score of three trials is obtained. It only requires a timer and balance foam to administer the test.
Timed Up and Go (TUG) TestChange from up to week 9 of treatment to up to 16 weeks of treatmentThe TUG is a test of balance and risk for falls.(8) This test measures the time it takes to walk 3 meters starting from a sitting position and it ends when the patient is seated again. Among the population studied for the TUG are the frail elderly and vestibular disorders.(9) The cut-off scores that indicate risk for falls are greater than 13.5 seconds for community dwelling older adults (8) and greater than 11.1 seconds for vestibular disorders.(10)
Dynamic Gait IndexChange from up to week 9 of treatment to up to 16 weeks of treatmentThe DGI assesses the ability to maintain balance while walking in the presence of external demands. It is scored based on a 4-point ordinal scale (3=no gait dysfunction, 2=minimal impairment, 1=moderate impairment and 0=severe impairment) with the highest possible score of 24.(11) A cut-off score of less than 19 is indicative of increased fall risks in community-dwelling elderlies.(12)
Dizziness Handicap Inventory (DHI)Change from up to week 9 of treatment to up to 16 weeks of treatmentThe DHI is a 25-item self-report questionnaire that quantifies the functional, emotional and physical impact of dizziness. Answers are graded 0 for no, 2 for sometimes and 4 for yes, with a maximum total score of 100. Interpretations are mild dizziness for scores between 0-30, moderate for 31-60 and severe for 61-100.(13)

Secondary

MeasureTime frameDescription
Total Number of VisitsFrom initial evaluation (day 1 of treatment) to up to 16 weeks of treatmentThe total number of visits after signing the informed consent between the three intervention groups were compared.
Length of Interventions in WeeksFrom initial evaluation (day 1 of treatment) to up to 16 weeks of treatmentThe length of interventions in weeks between the three intervention group will be compared.

Other

MeasureTime frameDescription
International Physical Activity Questionnaire (IPAQ)- WalkChange from up to week 9 of treatment to up to 4 weeks post treatmentThe IPAQ short form is an instrument evaluation tool of physical activity among the adults. It has three categories: low, moderate and high. The specific type of activities assessed are walking, moderate intensity activities and vigorous intensity activities. All continuous scores are expressed in MET-minutes/week with walking =3.3 METs, Moderate PA=4.0 METs and Vigorous PA = 8.0 METs. An overall total physical activity score can be computed as the sum of the total MET-minutes/week scores.(14)

Countries

United States

Participant flow

Recruitment details

The participants were recruited from July 2018 - September 2019 through consecutive admissions from two outpatient clinics with therapists with experience in VR.

Pre-assignment details

After the subject signed the informed consent, the study coordinator was notified by the research staff to conduct a retrospective chart review of the medical record of the subject. Based on the retrospective chart review, the study coordinator determined if the subject was eligible to participate in the study.

Participants by arm

ArmCount
VRWP Group
Vestibular Rehabilitation plus Walking with Pedometer Groupd VRWP Group: The VRWP group will have VR with an instruction to increase their number of steps daily to at least 3,000 steps using the pedometer (VR plus walking plus pedometer group). They will receive pedometers (Fitbit Zip), instructions on how to use the pedometer, step log forms, with home instruction handout to walk more at least more than ten minutes at a time. The participants will record on their activity log the number of steps shown on the step display at the end of the day. The daily step log form will be given to the research staff every visit for recording. The research staff will encourage their participants to increase their daily steps at least 10% until they achieve at least 3,000 steps daily.
3
VRW Group
Vestibular Rehabilitation plus Walking without Pedometer Group VRW Group: The VR (control) group will follow the conventional VR physical therapy without the encouragement of walking and without specification of walking in the home exercise program.
6
VR Group
Vestibular Rehabilitation Only Group. The VR (control) group will follow the conventional VR physical therapy without the encouragement of walking and without specification of walking in the home exercise program.
4
Total13

Withdrawals & dropouts

PeriodReasonFG000FG001FG002
Overall StudyBenign Paroxysmal Positional Vertigo001
Overall StudyHospitalization100
Overall StudyLost to Follow-up101

Baseline characteristics

CharacteristicVRWP GroupVRW GroupVR GroupTotal
Age, Continuous77.67 years
STANDARD_DEVIATION 10.41
81.17 years
STANDARD_DEVIATION 9.81
78.25 years
STANDARD_DEVIATION 8.81
79.03 years
STANDARD_DEVIATION 9.68
IPAQ-Total1046.67 METS-min/week
STANDARD_DEVIATION 805.75
2145.4 METS-min/week
STANDARD_DEVIATION 2667.75
3963.5 METS-min/week
STANDARD_DEVIATION 6573.74
2385.19 METS-min/week
STANDARD_DEVIATION 3349.08
IPAQ-Walk660 METS-min/week
STANDARD_DEVIATION 646.03
562.07 METS-min/week
STANDARD_DEVIATION 212.1
2293.5 METS-min/week
STANDARD_DEVIATION 4020.56
1171.86 METS-min/week
STANDARD_DEVIATION 1626.23
Race and Ethnicity Not Collected0 Participants
Sex: Female, Male
Female
2 Participants2 Participants2 Participants6 Participants
Sex: Female, Male
Male
1 Participants4 Participants2 Participants7 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
0 / 50 / 60 / 6
other
Total, other adverse events
0 / 50 / 60 / 6
serious
Total, serious adverse events
0 / 50 / 60 / 6

Outcome results

Primary

Dizziness Handicap Inventory (DHI)

The DHI is a 25-item self-report questionnaire that quantifies the functional, emotional and physical impact of dizziness. Answers are graded 0 for no, 2 for sometimes and 4 for yes, with a maximum total score of 100. Interpretations are mild dizziness for scores between 0-30, moderate for 31-60 and severe for 61-100.(13)

Time frame: Change from up to week 9 of treatment to up to 16 weeks of treatment

Population: Pretest and posttest means of VR (n=5), VRWP (n=4) and VRW (n=6) were presented. Another arm was added combining VRWP and VRW data into a group representing prescribed walking (n=10)

ArmMeasureGroupValue (MEAN)Dispersion
Control (VR) GroupDizziness Handicap Inventory (DHI)Pretest16 scoreStandard Deviation 22.56
Control (VR) GroupDizziness Handicap Inventory (DHI)Posttest13.2 scoreStandard Deviation 18.9
VRWP (Vestibular Rehabilitation With Walking With Pedometer)Dizziness Handicap Inventory (DHI)Posttest11.5 scoreStandard Deviation 9.71
VRWP (Vestibular Rehabilitation With Walking With Pedometer)Dizziness Handicap Inventory (DHI)Pretest38.5 scoreStandard Deviation 31.09
VRW (Vestibular Rehabilitation Walking Without a Pedometer)Dizziness Handicap Inventory (DHI)Pretest23.67 scoreStandard Deviation 13.65
VRW (Vestibular Rehabilitation Walking Without a Pedometer)Dizziness Handicap Inventory (DHI)Posttest7.33 scoreStandard Deviation 5.16
Prescribed Walking GroupDizziness Handicap Inventory (DHI)Pretest29.6 scoreStandard Deviation 22.01
Prescribed Walking GroupDizziness Handicap Inventory (DHI)Posttest9 scoreStandard Deviation 7.13
Comparison: Ho: There is no significant difference between the groups in DHI Ha: There is a significant difference between the groups in DHIp-value: 0.11Kruskal-Wallis
Comparison: Ho: There is no significant difference in DHI between the prescribed walking group and the control group Ha: There is a significant difference in DHI between the prescribed walking group and the control groupp-value: 0.04Kruskal-Wallis
Primary

Dynamic Gait Index

The DGI assesses the ability to maintain balance while walking in the presence of external demands. It is scored based on a 4-point ordinal scale (3=no gait dysfunction, 2=minimal impairment, 1=moderate impairment and 0=severe impairment) with the highest possible score of 24.(11) A cut-off score of less than 19 is indicative of increased fall risks in community-dwelling elderlies.(12)

Time frame: Change from up to week 9 of treatment to up to 16 weeks of treatment

Population: Pretest and posttest means of VR (n=5), VRWP (n=4) and VRW (n=6) were presented. Another arm was added combining VRWP and VRW data into a group representing prescribed walking (n=10)

ArmMeasureGroupValue (MEAN)Dispersion
Control (VR) GroupDynamic Gait IndexPretest20 scoreStandard Deviation 2.74
Control (VR) GroupDynamic Gait IndexPosttest22.80 scoreStandard Deviation 1.64
VRWP (Vestibular Rehabilitation With Walking With Pedometer)Dynamic Gait IndexPosttest22 scoreStandard Deviation 1.63
VRWP (Vestibular Rehabilitation With Walking With Pedometer)Dynamic Gait IndexPretest19.5 scoreStandard Deviation 2.38
VRW (Vestibular Rehabilitation Walking Without a Pedometer)Dynamic Gait IndexPretest20.67 scoreStandard Deviation 2.88
VRW (Vestibular Rehabilitation Walking Without a Pedometer)Dynamic Gait IndexPosttest22.67 scoreStandard Deviation 1.03
Prescribed Walking GroupDynamic Gait IndexPretest20.2 scoreStandard Deviation 2.62
Prescribed Walking GroupDynamic Gait IndexPosttest22.4 scoreStandard Deviation 1.26
Comparison: Ho: There is no significant difference between the groups in DGI Ha: There is a significant difference between the groups in DGIp-value: 0.67Kruskal-Wallis
Comparison: Ho: There is no significant difference between the prescribed walking group and the control group in DGI Ha: There is a significant difference between the prescribed walking group and control group in DGIp-value: 0.42Kruskal-Wallis
Primary

Modified Clinical Test of Sensory Integration for Balance (mCTSIB)

The mCTSIB quantifies the ability of the patient to use information from somatosensory, visual and vestibular system effectively for postural stability. This test eliminated conditions 3 and 6 of the original CTSIB, which use an altered visual input (visual conflict dome). It is performed with the feet together, a modification from the original test, which is with feet apart.(7) The four conditions of mCTSIB are standing on firm surface eyes open, standing on firm surface eyes closed, standing on compliant surface eyes open, and standing on compliant surface eyes closed. The patient is timed for 30 seconds and the average score of three trials is obtained. It only requires a timer and balance foam to administer the test.

Time frame: Change from up to week 9 of treatment to up to 16 weeks of treatment

Population: Pretest and posttest means of VR (n=5), VRWP (n=4) and VRW (n=6) were presented. Another arm was added combining VRWP and VRW data into a group representing prescribed walking (n=10)

ArmMeasureGroupValue (MEAN)Dispersion
Control (VR) GroupModified Clinical Test of Sensory Integration for Balance (mCTSIB)Pretest115.98 secondsStandard Deviation 5.82
Control (VR) GroupModified Clinical Test of Sensory Integration for Balance (mCTSIB)Posttest120 secondsStandard Deviation 0
VRWP (Vestibular Rehabilitation With Walking With Pedometer)Modified Clinical Test of Sensory Integration for Balance (mCTSIB)Posttest111.17 secondsStandard Deviation 10.234
VRWP (Vestibular Rehabilitation With Walking With Pedometer)Modified Clinical Test of Sensory Integration for Balance (mCTSIB)Pretest97.4 secondsStandard Deviation 5.78
VRW (Vestibular Rehabilitation Walking Without a Pedometer)Modified Clinical Test of Sensory Integration for Balance (mCTSIB)Pretest110.15 secondsStandard Deviation 9.97
VRW (Vestibular Rehabilitation Walking Without a Pedometer)Modified Clinical Test of Sensory Integration for Balance (mCTSIB)Posttest118 secondsStandard Deviation 3.35
Prescribed Walking GroupModified Clinical Test of Sensory Integration for Balance (mCTSIB)Pretest107.23 secondsStandard Deviation 10.55
Prescribed Walking GroupModified Clinical Test of Sensory Integration for Balance (mCTSIB)Posttest115.27 secondsStandard Deviation 7.23
Comparison: Ho: There is no significant difference between groups in mCTSIB Ha: There is a significant difference between groups in mCTSIBp-value: 0.64Kruskal-Wallis
Comparison: Ho: There is no significant difference between the prescribed walking group and the control group in mCTSIB Ha: There is a significant difference between the prescribed walking group and the control group in mCTSIBp-value: 0.18Kruskal-Wallis
Primary

Timed Up and Go (TUG) Test

The TUG is a test of balance and risk for falls.(8) This test measures the time it takes to walk 3 meters starting from a sitting position and it ends when the patient is seated again. Among the population studied for the TUG are the frail elderly and vestibular disorders.(9) The cut-off scores that indicate risk for falls are greater than 13.5 seconds for community dwelling older adults (8) and greater than 11.1 seconds for vestibular disorders.(10)

Time frame: Change from up to week 9 of treatment to up to 16 weeks of treatment

Population: Pretest and posttest means of VR (n=5), VRWP (n=4) and VRW (n=6) were presented. Another arm was added combining VRWP and VRW data into a group representing prescribed walking (n=10).

ArmMeasureGroupValue (MEAN)Dispersion
Control (VR) GroupTimed Up and Go (TUG) TestPretest10 secondsStandard Deviation 1.64
Control (VR) GroupTimed Up and Go (TUG) TestPosttest7.80 secondsStandard Deviation 1.3
VRWP (Vestibular Rehabilitation With Walking With Pedometer)Timed Up and Go (TUG) TestPosttest10 secondsStandard Deviation 3.46
VRWP (Vestibular Rehabilitation With Walking With Pedometer)Timed Up and Go (TUG) TestPretest12.73 secondsStandard Deviation 3.54
VRW (Vestibular Rehabilitation Walking Without a Pedometer)Timed Up and Go (TUG) TestPretest12.42 secondsStandard Deviation 5.75
VRW (Vestibular Rehabilitation Walking Without a Pedometer)Timed Up and Go (TUG) TestPosttest10.92 secondsStandard Deviation 5.12
Prescribed Walking GroupTimed Up and Go (TUG) TestPretest12.54 secondsStandard Deviation 4.75
Prescribed Walking GroupTimed Up and Go (TUG) TestPosttest10.55 secondsStandard Deviation 4.34
Comparison: Ho: There is no significant difference between the groups in TUG Ha: There is a significant difference between the groups in TUGp-value: 0.67Kruskal-Wallis
Comparison: Ho: There is no significant difference in TUG between the prescribed walking and control group Ha: There is a significant difference in TUG between the prescribed walking and control groupp-value: 0.71Kruskal-Wallis
Secondary

Length of Interventions in Weeks

The length of interventions in weeks between the three intervention group will be compared.

Time frame: From initial evaluation (day 1 of treatment) to up to 16 weeks of treatment

Population: Means and Standard Deviations of VR (n=5), VRWP (n=4) and VRW (n=6) were presented. Another arm was added combining VRWP and VRW data into a group representing prescribed walking (n=10)

ArmMeasureValue (MEAN)Dispersion
Control (VR) GroupLength of Interventions in Weeks8.5 weeksStandard Deviation 1.41
VRWP (Vestibular Rehabilitation With Walking With Pedometer)Length of Interventions in Weeks9.25 weeksStandard Deviation 1.65
VRW (Vestibular Rehabilitation Walking Without a Pedometer)Length of Interventions in Weeks8.5 weeksStandard Deviation 1.98
Prescribed Walking GroupLength of Interventions in Weeks8.88 weeksStandard Deviation 1.82
Secondary

Total Number of Visits

The total number of visits after signing the informed consent between the three intervention groups were compared.

Time frame: From initial evaluation (day 1 of treatment) to up to 16 weeks of treatment

Population: There are 5 participants in the Control (Vestibular Rehabilitation) Group and 10 Walking Group. Participants in the Walking Group received a prescribed walking program in the form of pedometer (Vestibular Rehabilitation plus walking with pedometer or VRWP N=4 and timed-walking (Vestibular Rehabilitation plus walking without Pedometer or VRW N=6).

ArmMeasureValue (MEAN)Dispersion
Control (VR) GroupTotal Number of Visits5.6 visitsStandard Deviation 1.03
VRWP (Vestibular Rehabilitation With Walking With Pedometer)Total Number of Visits6.75 visitsStandard Deviation 1.89
VRW (Vestibular Rehabilitation Walking Without a Pedometer)Total Number of Visits7.33 visitsStandard Deviation 1.89
Prescribed Walking GroupTotal Number of Visits7.04 visitsStandard Deviation 1.89
Other Pre-specified

International Physical Activity Questionnaire (IPAQ)- Walk

The IPAQ short form is an instrument evaluation tool of physical activity among the adults. It has three categories: low, moderate and high. The specific type of activities assessed are walking, moderate intensity activities and vigorous intensity activities. All continuous scores are expressed in MET-minutes/week with walking =3.3 METs, Moderate PA=4.0 METs and Vigorous PA = 8.0 METs. An overall total physical activity score can be computed as the sum of the total MET-minutes/week scores.(14)

Time frame: Change from up to week 9 of treatment to up to 4 weeks post treatment

Population: IPAQ-Walk scores were categorized as increase if there was an increase in four-weeks follow-up score compared to pretest score, same if there was no change in four-weeks follow-up score compared to pretest score, and decrease if there was a decline in four-weeks follow-up score compared to pretest score.

ArmMeasureGroupValue (NUMBER)
Control (VR) GroupInternational Physical Activity Questionnaire (IPAQ)- Walksame0 participants
Control (VR) GroupInternational Physical Activity Questionnaire (IPAQ)- Walkincrease3 participants
Control (VR) GroupInternational Physical Activity Questionnaire (IPAQ)- Walkdecrease0 participants
VRWP (Vestibular Rehabilitation With Walking With Pedometer)International Physical Activity Questionnaire (IPAQ)- Walksame0 participants
VRWP (Vestibular Rehabilitation With Walking With Pedometer)International Physical Activity Questionnaire (IPAQ)- Walkincrease4 participants
VRWP (Vestibular Rehabilitation With Walking With Pedometer)International Physical Activity Questionnaire (IPAQ)- Walkdecrease2 participants
VRW (Vestibular Rehabilitation Walking Without a Pedometer)International Physical Activity Questionnaire (IPAQ)- Walkincrease2 participants
VRW (Vestibular Rehabilitation Walking Without a Pedometer)International Physical Activity Questionnaire (IPAQ)- Walkdecrease2 participants
VRW (Vestibular Rehabilitation Walking Without a Pedometer)International Physical Activity Questionnaire (IPAQ)- Walksame0 participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026